Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
June 16, 2024 05:30 ET
|
Nurix Therapeutics, Inc.
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and...
Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
June 15, 2024 10:00 ET
|
F. Hoffmann-La Roche Ltd
The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with Columvi...
Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress
June 15, 2024 08:45 ET
|
Agios Pharmaceuticals, Inc.
– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional ENERGIZE Poster Presentation Highlights...
Galapagos presenteert bemoedigende nieuwe resultaten voor CD19 CAR-T kandidaat GLPG5101 in non-Hodgkin lymfoom op EHA 2024
June 14, 2024 16:01 ET
|
Galapagos NV
Mechelen, België; 14 juni 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) kondigde vandaag aan dat het bemoedigende nieuwe resultaten zal presenteren van de lopende fase 1/2 ATALANTA-1...
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024
June 14, 2024 16:01 ET
|
Galapagos NV
Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19...
Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)
June 14, 2024 13:41 ET
|
Scilex Holding Company
The Phase 3 study results are being published in PAIN® Journal, which is the leading journal devoted to pain medicine and research. PAIN is the official journal of the International Association for...
LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
June 14, 2024 11:00 ET
|
Lixte Biotechnology Holdings, Inc.
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE...
TALVEY®▼ (talquetamab) demonstrated highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
June 14, 2024 08:10 ET
|
Janssen Cilag International NV
24-month overall survival rate of 67 percent achieved with talquetamab 0.8mg/kg biweekly dosing in the Phase 1/2 MonumenTAL-1 study1 BEERSE, BELGIUM , June 14, 2024 (GLOBE NEWSWIRE) --...
Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress
June 14, 2024 08:00 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
June 14, 2024 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 84th Scientific...